TREATMENTS OF CANCER EXPRESSING MUTANT EGF RECEPTORS Russian patent published in 2011 - IPC A61K39/395 A61P35/00 

FIELD: medicine.

SUBSTANCE: group of inventions can be used for detection of epidermal growth factor receptor (EGFR) antibodies reducing or preventing signal transmission by intact EGFR or EGFRvIII. The methods under the invention include (a) contact of a candidate antibody with EGFR protein or its fragment having wild-type EGFR, (b) contact of the candidate antibody with EGFR protein or its fragment having mutant EGFR, comparison of binding of the candidate antibody with EGFR protein or its fragment, at the stage (a) with binding of the candidate antibody with EGFR protein or its fragment at the stage (b), and the antibody binding with EGFR at the stage (a), not at the stage (b) is identified as an anti-EGFR antibody which decreases or prevents signal transmission by intact EGFR or EGFRvIII.

EFFECT: use of inventions enables to identify the antibodies inhibiting signal transduction by intact EGFR.

19 cl, 9 dwg, 3 tbl, 4 ex